ALSO NOTED: Dutch court ruling protects Pfizer's Lipitor; J&J loses bid to dismiss whistleblower suit;

> Pfizer announced that a Dutch court ruled to prevent generics maker Ranbaxy from launching a copycat form of the best-selling Lipitor. Report

> Pfizer has demonstrated once again just how interested it is in biotech with its $195 million deal to buy Encysive. Report

> A federal judge denied Johnson & Johnson's attempt to get a whistleblower suit dismissed; the suit involves charges that J&J's Ortho-McNeil unit offered kickbacks to hospitals that purchased more of its Levaquin antibiotic than a rival med. Report

> Danish drug maker Lifecycle Pharma has launched its cholesterol med Fenoglide in the U.S., marketing it through U.S. partner Sciele Pharma. Release

> India's Aurobindo Pharma is investing $14.7 million in a manufacturing plant in Malta, planning to use it to strengthen its presence in Europe. Report

> The FDA gave its blessing to a new liquid allergy medication, Xyzal, made by UCB and Sanofi-Aventis; the drug's tablet form was approved in May 2007. Report

> An FDA advisory panel agreed Wednesday that GlaxoSmithKline's Rotarix vaccine was safe and effective, recommending the anti-rotavirus shot for agency approval. If approved for sale, Rotarix will compete with Merck's RotaTeq, which has been on the market since 2006. Report

> A Nobel Prize-winning biologist says that researchers are no closer to developing a vaccine against HIV than they were 20 years ago, when the scientific quest began. Report

> Can a vaccine control high blood pressure? Report

> There's growing evidence around the U.S. that the flu jab offers only marginal protection against the seasonal ailment. Report

And Finally... Is this a pharma opportunity? New research in Nature shows new infectious diseases are emerging at a rapid pace. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.